Publications
11
Citations
87
Est. group size
~2
Recurring co-author estimate
Active years
8
Publishing since 2018
Neel Rajan's research focuses on thyroid cancer biology, particularly how certain cell-signaling pathways (such as MAPK, AKT, and PAK) drive cancer cell growth and how these cancers respond to drugs that block specific proteins involved in cell division and gene activity (like CDK7/9 and PAK inhibitors). This work aims to identify potential drug targets for treating thyroid cancer. An earlier publication also examined how caffeine affects an enzyme involved in starch digestion, suggesting some breadth beyond the core cancer focus.
Publication output has been low but fairly steady over the last decade, with occasional small upticks (such as in 2020 and 2022) and gaps in other years, averaging about one to two papers per year recently.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- MON-LB80 Human Thyroid Cancer Cells Are Highly Sensitive to CDK7 and 9 Inhibition
Journal of the Endocrine Society · 2020
- MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition
Endocrine Related Cancer · 2019
- Inactivation of α-Amylase by Caffeine: Reducing the Break-down of Starch into Sugars
American Journal of Bioscience and Bioengineering · 2018
- Journal of the Endocrine Society×4
- Endocrine Related Cancer×2
- Thyroid×2
- Endocrine×1
- Biofabrication×1
- Matthew D. Ringel
Medicine · The Ohio State University
- Anisley Valenciaga
Medicine · The Ohio State University
- Huihao Zhang
Medicine · The Ohio State University
- Ernest L. Mazzaferri
Medicine · The Ohio State University
- Fadi Nabhan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile